BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 17133560)

  • 1. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
    Verpoort KN; Jol-van der Zijde CM; Papendrecht-van der Voort EA; Ioan-Facsinay A; Drijfhout JW; van Tol MJ; Breedveld FC; Huizinga TW; Toes RE
    Arthritis Rheum; 2006 Dec; 54(12):3799-808. PubMed ID: 17133560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
    Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles.
    Verpoort KN; Papendrecht-van der Voort EA; van der Helm-van Mil AH; Jol-van der Zijde CM; van Tol MJ; Drijfhout JW; Breedveld FC; de Vries RR; Huizinga TW; Toes RE
    Arthritis Rheum; 2007 Sep; 56(9):2913-8. PubMed ID: 17763436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis.
    van der Woude D; Rantapää-Dahlqvist S; Ioan-Facsinay A; Onnekink C; Schwarte CM; Verpoort KN; Drijfhout JW; Huizinga TW; Toes RE; Pruijn GJ
    Ann Rheum Dis; 2010 Aug; 69(8):1554-61. PubMed ID: 20448290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis.
    Verpoort KN; van Gaalen FA; van der Helm-van Mil AH; Schreuder GM; Breedveld FC; Huizinga TW; de Vries RR; Toes RE
    Arthritis Rheum; 2005 Oct; 52(10):3058-62. PubMed ID: 16200610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis.
    Candia L; Marquez J; Gonzalez C; Santos AM; Londoño J; Valle R; Zabaleta J; Yaqub Z; Espinoza LR
    J Clin Rheumatol; 2006 Oct; 12(5):226-9. PubMed ID: 17023808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
    Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
    Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
    Mikuls TR; O'Dell JR; Stoner JA; Parrish LA; Arend WP; Norris JM; Holers VM
    Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies.
    Jaskowski TD; Hill HR; Russo KL; Lakos G; Szekanecz Z; Teodorescu M
    J Rheumatol; 2010 Aug; 37(8):1582-8. PubMed ID: 20516016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
    Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders.
    Anzilotti C; Riente L; Pratesi F; Chimenti D; Delle Sedie A; Bombardieri S; Migliorini P
    Rheumatology (Oxford); 2007 Oct; 46(10):1579-82. PubMed ID: 17717033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).
    Kastbom A; Strandberg G; Lindroos A; Skogh T
    Ann Rheum Dis; 2004 Sep; 63(9):1085-9. PubMed ID: 15308517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis.
    Sihvonen S; Korpela M; Mustila A; Mustonen J
    J Rheumatol; 2005 Nov; 32(11):2089-94. PubMed ID: 16265684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.
    Nielen MM; van Schaardenburg D; Reesink HW; van de Stadt RJ; van der Horst-Bruinsma IE; de Koning MH; Habibuw MR; Vandenbroucke JP; Dijkmans BA
    Arthritis Rheum; 2004 Feb; 50(2):380-6. PubMed ID: 14872479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
    Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
    J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles.
    Snir O; Widhe M; von Spee C; Lindberg J; Padyukov L; Lundberg K; Engström A; Venables PJ; Lundeberg J; Holmdahl R; Klareskog L; Malmström V
    Ann Rheum Dis; 2009 May; 68(5):736-43. PubMed ID: 18635594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.